Eastgate Biotech Corp. (ETBI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Eastgate Biotech Corp. (ETBI) with AI Score 39/100 (Weak). EastGate Biotech Corp. is a pharmaceutical company focused on developing and distributing nutraceuticals based on natural therapies, utilizing nanotechnologies for enhanced delivery. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Eastgate Biotech Corp. (ETBI) Healthcare & Pipeline Overview
EastGate Biotech Corp. operates in the pharmaceutical sector, focusing on nutraceuticals and natural therapies delivered through advanced nanotechnologies. The company aims to offer alternatives to traditional pharmaceuticals, targeting health-conscious consumers. With a small team and a diverse product portfolio, EastGate seeks to establish a niche in the competitive healthcare market.
Investment Thesis
EastGate Biotech Corp. presents a high-risk, high-reward investment opportunity within the nutraceutical and pharmaceutical sector. The company's focus on nanotechnology-enhanced delivery systems for natural therapies could provide a competitive edge. However, the company's negative profit margin of -3553.7% and gross margin of -110.4% raise concerns about its financial sustainability. The company's small market capitalization of $0.00B and high beta of 3.42 indicate significant volatility. Growth catalysts include potential partnerships, new product launches, and expansion into new markets. Investors should carefully consider the company's financial position and the competitive landscape before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- P/E Ratio of -0.54 reflects negative earnings, suggesting the company is currently not profitable.
- Profit Margin of -3553.7% indicates substantial losses, requiring careful evaluation of the company's financial stability.
- Gross Margin of -110.4% suggests that the cost of goods sold exceeds revenue, highlighting operational inefficiencies.
- Beta of 3.42 indicates high volatility compared to the market, implying a higher risk investment.
Competitors & Peers
Strengths
- Innovative nanotechnology delivery systems.
- Focus on natural therapies and nutraceuticals.
- Diverse product portfolio.
- Offices in multiple locations.
Weaknesses
- Small company size with only 2 employees.
- Negative profit and gross margins.
- Limited financial resources.
- High beta indicating high volatility.
Catalysts
- Upcoming: Potential partnerships with distributors to expand market reach.
- Upcoming: Launch of new nutraceutical products targeting specific health conditions.
- Ongoing: Continued research and development of nanotechnology-enhanced delivery systems.
Risks
- Potential: Intense competition from established pharmaceutical companies.
- Potential: Regulatory hurdles and compliance requirements.
- Ongoing: Limited financial resources and negative profit margins.
- Ongoing: High beta indicating high volatility.
- Potential: Product development and clinical trial risks.
Growth Opportunities
- Expansion into New Therapeutic Areas: EastGate Biotech Corp. can expand its product portfolio by developing nutraceuticals targeting new therapeutic areas, such as cardiovascular health, cognitive function, and immune support. The market for these products is substantial, with a global market size estimated at billions of dollars. Successful expansion into these areas could significantly increase EastGate's revenue and market share. Timeline: 1-3 years.
- Strategic Partnerships with Distributors: Forming strategic partnerships with distributors can expand EastGate Biotech Corp.'s reach and market penetration. Collaborating with established distributors in key markets can accelerate product adoption and increase sales volume. This strategy can leverage the distributors' existing infrastructure and customer relationships. Timeline: 6-12 months.
- Development of Novel Delivery Systems: EastGate Biotech Corp. can invest in the research and development of novel delivery systems for its nutraceuticals. This can involve exploring new nanotechnology applications, such as liposomes, micelles, and dendrimers. Developing innovative delivery systems can enhance the efficacy and bioavailability of its products, providing a competitive advantage. Timeline: 2-5 years.
- Geographic Expansion into Emerging Markets: Expanding into emerging markets, such as Asia and Latin America, can provide EastGate Biotech Corp. with significant growth opportunities. These markets have a growing middle class and increasing demand for healthcare products. Entering these markets requires adapting products to local preferences and regulatory requirements. Timeline: 1-3 years.
- Direct-to-Consumer (DTC) Sales Channels: Establishing direct-to-consumer sales channels, such as online stores and subscription services, can increase EastGate Biotech Corp.'s control over its distribution and pricing. This strategy can also enable the company to build direct relationships with customers and gather valuable feedback. Investing in digital marketing and e-commerce infrastructure is essential for success. Timeline: 6-12 months.
Opportunities
- Expansion into new therapeutic areas.
- Strategic partnerships with distributors.
- Development of novel delivery systems.
- Geographic expansion into emerging markets.
Threats
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles and compliance requirements.
- Product development and clinical trial risks.
- Economic downturn affecting consumer spending.
Competitive Advantages
- Proprietary nanotechnology-enhanced delivery systems.
- Focus on natural therapies and nutraceuticals.
- Brand reputation for providing healthier alternatives.
About ETBI
EastGate Biotech Corp., a pharmaceutical company, was founded with the mission to develop and distribute nutraceuticals that leverage natural therapies and are absorbed naturally by the body. The company employs state-of-the-art nanotechnologies to enhance the delivery of these nutraceuticals, positioning them as alternatives to conventional pharmaceuticals. EastGate's product portfolio includes E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X, addressing various health and wellness needs. The company develops products by incorporating components into nano-sized delivery vectors, such as nanoemulsions, nanoparticles, and hybrid nanoparticles. These advanced delivery systems aim to improve the efficacy and bioavailability of the nutraceuticals. EastGate Biotech Corp. maintains a presence with offices in New York, London SF, Cockfosters BP, Los Angeles, Chicago, and Las Vegas, indicating a broad geographic footprint despite its small size. The company aims to provide consumers with healthier alternatives to traditional pharmaceutical products, focusing on natural ingredients and advanced delivery methods.
What They Do
- Develops nutraceutical products based on natural therapies.
- Utilizes nanotechnology to enhance the delivery of its products.
- Offers alternatives to conventional pharmaceuticals.
- Distributes products through various channels.
- Focuses on products that are naturally absorbed by the body.
- Aims to provide healthier alternatives to traditional medicine.
Business Model
- Develops and manufactures nutraceutical products.
- Distributes products through various channels, including online and retail.
- Generates revenue through the sale of its products.
Industry Context
EastGate Biotech Corp. operates in the nutraceutical and pharmaceutical industry, which is experiencing growth driven by increasing consumer interest in natural health solutions and preventative care. The market is competitive, with established pharmaceutical companies and emerging nutraceutical brands vying for market share. EastGate's focus on nanotechnology-enhanced delivery systems differentiates it from competitors. However, the company faces challenges related to regulatory approvals, product development costs, and marketing expenses. The nutraceutical market is projected to continue growing, driven by aging populations and increasing healthcare costs.
Key Customers
- Health-conscious consumers seeking natural alternatives to pharmaceuticals.
- Individuals looking for products with fewer side effects.
- Consumers interested in preventative healthcare and wellness.
Financials
Chart & Info
Eastgate Biotech Corp. (ETBI) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Nov 5, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ETBI.
Price Targets
Wall Street price target analysis for ETBI.
MoonshotScore
What does this score mean?
The MoonshotScore rates ETBI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Rosella C. Perri
CEO
Rosella C. Perri serves as the CEO of EastGate Biotech Corp. Her background includes experience in managing small teams and overseeing the operations of a pharmaceutical company. She is responsible for the strategic direction and overall performance of the company. Her leadership is focused on driving innovation and expanding the company's product portfolio. She has a strong understanding of the nutraceutical and pharmaceutical industries.
Track Record: Under Rosella C. Perri's leadership, EastGate Biotech Corp. has focused on developing and distributing nutraceutical products based on natural therapies. She has overseen the implementation of nanotechnology-enhanced delivery systems. Her strategic decisions have aimed to position the company as a provider of healthier alternatives to traditional pharmaceuticals. However, the company's financial performance remains a challenge.
ETBI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that EastGate Biotech Corp. may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to adhere to strict reporting standards. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like NYSE or NASDAQ. This tier is often populated by shell companies, companies with financial difficulties, or those that choose not to meet higher listing standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the company's debt and liabilities.
- Understand the company's business model and revenue streams.
- Consult with a financial advisor.
- Company has been in operation for several years.
- Presence of offices in multiple locations.
- Development of a diverse product portfolio.
- Focus on nanotechnology and innovation.
- CEO with experience in the pharmaceutical industry.
Common Questions About ETBI
What does Eastgate Biotech Corp. do?
EastGate Biotech Corp. is a pharmaceutical company that develops, produces, and distributes nutraceuticals based on natural therapies. The company utilizes state-of-the-art nanotechnologies to enhance the delivery of these nutraceuticals, aiming to provide healthier alternatives to conventional pharmaceuticals. Its product portfolio includes E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X, addressing various health and wellness needs. The company focuses on incorporating components into nano-sized delivery vectors to improve efficacy.
What do analysts say about ETBI stock?
AI analysis is currently pending for ETBI. Given the company's OTC Other listing and limited financial disclosure, analyst coverage is likely to be minimal. Investors should conduct their own thorough research and due diligence before considering an investment in ETBI. Key valuation metrics, such as P/E ratio and profit margin, indicate financial challenges. Growth considerations include potential partnerships and new product launches, but these are subject to significant risks.
What are the main risks for ETBI?
The main risks for EastGate Biotech Corp. include intense competition from established pharmaceutical companies, regulatory hurdles and compliance requirements, limited financial resources, and high volatility. The company's negative profit and gross margins raise concerns about its financial sustainability. Additionally, product development and clinical trial risks are inherent in the pharmaceutical industry. The company's OTC Other listing adds further risks related to limited disclosure and liquidity.
What are the key factors to evaluate for ETBI?
Eastgate Biotech Corp. (ETBI) currently holds an AI score of 39/100, indicating low score. Key strength: Innovative nanotechnology delivery systems.. Primary risk to monitor: Potential: Intense competition from established pharmaceutical companies.. This is not financial advice.
How frequently does ETBI data refresh on this page?
ETBI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ETBI's recent stock price performance?
Recent price movement in Eastgate Biotech Corp. (ETBI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative nanotechnology delivery systems.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ETBI overvalued or undervalued right now?
Determining whether Eastgate Biotech Corp. (ETBI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ETBI?
Before investing in Eastgate Biotech Corp. (ETBI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC Other listing and unknown disclosure status.
- AI analysis pending.